OTCM
FRTX
Market cap5mUSD
Feb 28, Last price
0.94USD
Name
Fresh Tracks Therapeutics Inc
Chart & Performance
Profile
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 8,006 15.31% | 6,943 1,618.56% | |||||||
Cost of revenue | 14,366 | 42,520 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (6,360) | (35,577) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (441) | ||||||||
Tax Rate | |||||||||
NOPAT | (6,360) | (35,136) | |||||||
Net income | (5,694) -72.44% | (20,661) -47.72% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 6,569 | 1,233 | |||||||
BB yield | -126.38% | -29.27% | |||||||
Debt | |||||||||
Debt current | 49 | ||||||||
Long-term debt | 49 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 620 | ||||||||
Net debt | (10,868) | (8,582) | |||||||
Cash flow | |||||||||
Cash from operating activities | (4,343) | (19,335) | |||||||
CAPEX | (47) | ||||||||
Cash from investing activities | (47) | ||||||||
Cash from financing activities | 6,531 | 1,178 | |||||||
FCF | (6,270) | (35,143) | |||||||
Balance | |||||||||
Cash | 10,868 | 8,680 | |||||||
Long term investments | |||||||||
Excess cash | 10,468 | 8,333 | |||||||
Stockholders' equity | (172,103) | (166,439) | |||||||
Invested Capital | 182,033 | 173,682 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 5,913 | 2,808 | |||||||
Price | 0.88 -41.39% | 1.50 -85.44% | |||||||
Market cap | 5,198 23.40% | 4,212 -77.09% | |||||||
EV | (5,670) | (4,370) | |||||||
EBITDA | (6,319) | (35,547) | |||||||
EV/EBITDA | 0.90 | 0.12 | |||||||
Interest | 5 | 9 | |||||||
Interest/NOPBT |